Get the Stockscreener App
38.40
0.21%
-0.08
After Hours:
38.40
Indivior Pharmaceuticals Inc stock is traded at $38.40, with a volume of 1.15M.
It is down -0.21% in the last 24 hours and up +4.46% over the past month.
Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company derives revenues from customers through the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company's products include: Sublocade (buprenorphine extended-release monthly injection), and Suboxone (buprenorphine and naloxone sublingual film).
See More
Previous Close:
$38.48
Open:
$38.69
24h Volume:
1.15M
Relative Volume:
0.48
Market Cap:
$4.54B
Revenue:
$1.29B
Net Income/Loss:
$251.00M
P/E Ratio:
19.45
EPS:
1.9744
Net Cash Flow:
$-193.86M
1W Performance:
+2.70%
1M Performance:
+4.46%
6M Performance:
+9.03%
1Y Performance:
+176.46%
1-Day Range:
$37.79
$38.94
1-Week Range:
$37.53
$38.94
52-Week Range:
$13.45
$41.00
Indivior Pharmaceuticals Inc Stock (INDV) Company Profile
Name
Indivior Pharmaceuticals Inc
Sector
Phone
804-379-1090
Address
10710 MIDLOTHIAN TURNPIKE, NORTH CHESTERFIELD
Compare INDV vs TAK, HLN, TEVA, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INDV
Indivior Pharmaceuticals Inc
|
38.40 | 4.55B | 1.29B | 251.00M | -193.86M | 1.9744 |
TAK
Takeda Pharmaceutical Co Adr
|
15.77 | 50.27B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.07 | 40.31B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
33.69 | 40.32B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
79.95 | 33.36B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
549.57 | 23.17B | 3.17B | 1.29B | 1.01B | 27.09 |
Indivior Pharmaceuticals Inc Stock (INDV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-06-25 | Initiated | H.C. Wainwright | Buy |
| Jul-22-25 | Resumed | Jefferies | Buy |
| Jan-28-25 | Initiated | Rodman & Renshaw | Buy |
| Jul-23-24 | Initiated | Piper Sandler | Overweight |
| Apr-03-24 | Initiated | Craig Hallum | Buy |
| Jul-13-23 | Initiated | Northland Capital | Outperform |
View All
Indivior Pharmaceuticals Inc Stock (INDV) Latest News
How Investors Are Reacting To Indivior (INDV) Upgraded 2026 Outlook And $175 Million Buyback Plan - Yahoo Finance
Indivior's Chief Scientific Officer Sold Over 18,000 Company Shares. Should Investors Worry? - Yahoo Finance
Is Indivior Pharmaceuticals, Inc. (INDV) A Good Stock To Buy Now? - Insider Monkey
Recent price trend in Indivior Pharmaceuticals Inc. (INDV) is your friend, here's why - MSN
Indivior Pharmaceuticals Inc (INDV) Insider Sell: Christian Heid - GuruFocus
Indivior (INDV) Chief Scientific Officer sells 18,586 shares under 10b5-1 plan - Stock Titan
INDV and the Shift to Long-Acting Opioid Use Disorder Care in 2026 - Yahoo Finance
Is Indivior Stock a Buy After Higher 2026 Guidance? - Yahoo Finance
INDV Stock: What Sublocade Growth Signals for 2026 - Yahoo Finance
Immunovant Stock Gains 12.4% in a Month: What's Driving It? - TradingView
Recent Price Trend in Indivior Pharmaceuticals Inc. (INDV) is Your Friend, Here's Why - Yahoo Finance
Indivior Pharmaceuticals Inc. (INDV) is a great momentum stock: Should you buy? - MSN
[144] Indivior Pharmaceuticals, Inc. SEC Filing - Stock Titan
HROW Stock Rises on Relaunch of Ophthalmology Drug Verkazia in the US - TradingView
A Look At Indivior Pharmaceuticals (INDV) Valuation After Strong Multi Period Share Price Gains - Yahoo Finance
Indivior CFO Ryan Preblick sells $1.36m in company stock By Investing.com - Investing.com Australia
Indivior Pharmaceuticals Inc (INDV) CFO Ryan Preblick Sells 36,0 - GuruFocus
Sanofi Ends Late-Stage Study on Neurology Drug Over Weak Results - TradingView
Indivior CFO Ryan Preblick sells $1.36m in company stock - Investing.com
Indivior Pharmaceuticals Insider Sold Shares Worth $1,357,200, According to a Recent SEC Filing - Moomoo
[Form 4] Indivior Pharmaceuticals, Inc. Insider Trading Activity - Stock Titan
Indivior: A Stronger Business Than When I First Covered It (NASDAQ:INDV) - Seeking Alpha
Amended Form 144: INDV (NASDAQ: INDV) lists 36,000-share sale via Fidelity - Stock Titan
INDV (NASDAQ) proposes sale of 36,000 shares; $1.36M aggregate listed - Stock Titan
Indivior Pharmaceuticals, Inc. Statistics – LSX:A42086 - TradingView
Indivior (INDV) Hovers Near Resistance Amid Modest Gains – Key Levels in FocusOrder Block - newsline.com
Indivior Pharmaceuticals (INDV) Holds Steady Near Key Support Amidst Cautious TradingIchimoku Entry - newsline.com
Operating expenses (excl. COGS) of Indivior Pharmaceuticals, Inc. – XETR:E7P - TradingView
ALVO Stock Gains 19% on FDA Resubmission of Biosimilar BLAs - TradingView
Indivior PLC stock (GB00BYZ0C031): shares trade quietly as investors focus on valuation metrics - AD HOC NEWS
INDV Technical Analysis | Trend, Signals & Chart Patterns | INDIVIOR PHARMACEUTICALS INC (NASDAQ:INDV) - ChartMill
Indivior Pharmaceuticals Inc (INDV) Stock Up 5.1% but GF Value S - GuruFocus
Net margin % of Indivior Pharmaceuticals, Inc. – LSX:A42086 - TradingView
Quick ratio of Indivior Pharmaceuticals, Inc. – LSX:A42086 - TradingView
Diluted net income available to common stockholders of Indivior Pharmaceuticals, Inc. – LSX:A42086 - TradingView
After tax other income/expense of Indivior Pharmaceuticals, Inc. – LSX:A42086 - TradingView
Non-controlling/minority interest of Indivior Pharmaceuticals, Inc. – LSX:A42086 - TradingView
Book value per share of Indivior Pharmaceuticals, Inc. – LSX:A42086 - TradingView
Operating income of Indivior Pharmaceuticals, Inc. – LSX:A42086 - TradingView
Diluted earnings per share (diluted EPS) of Indivior Pharmaceuticals, Inc. – LSX:A42086 - TradingView
Indivior Pharmaceuticals, Inc. Income Statement – LSX:A42086 - TradingView
Total debt per share of Indivior Pharmaceuticals, Inc. – LSX:A42086 - TradingView
Cash per share of Indivior Pharmaceuticals, Inc. – LSX:A42086 - TradingView
ETFs Investing in Indivior Pharmaceuticals, Inc. Stocks - TradingView
EBITDA margin % of Indivior Pharmaceuticals, Inc. – LSX:A42086 - TradingView
Price to earnings ratio of Indivior Pharmaceuticals, Inc. – LSX:A42086 - TradingView
Net income of Indivior Pharmaceuticals, Inc. – LSX:A42086 - TradingView
Zacks.com featured highlights include Indivior, ReNew Energy, Lifetime, NetScout and TEEKAY - The Globe and Mail
Indivior Pharmaceuticals Drops 6.3% Amid Sector-Wide Selling - AlphaStreet
Indivior Pharmaceuticals (NASDAQ:INDV) Passes Minervini Trend Template and High Growth Momentum Screen - ChartMill
Herantis reports positive FDA feedback and finalizes Phase 2a study design for HER-096 - GlobeNewswire Inc.
Indivior Pharmaceuticals Inc Stock (INDV) Financials Data
Revenue
Net Income
Cash Flow
EPS
9.24%
0.23%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):